Results 11 to 20 of about 3,026 (154)

Myxopyronin B inhibits growth of a Fidaxomicin-resistant Clostridioides difficile isolate and interferes with toxin synthesis

Gut Pathogens, 2022
The anaerobic, gastrointestinal pathogen Clostridioides difficile can cause severe forms of enterocolitis which is mainly mediated by the toxins it produces.
Madita Brauer, Jennifer Herrmann, Daniela Zühlke, Rolf Müller, Katharina Riedel, Susanne Sievers   +5 more
doaj   +1 more source

Does Fidaxomicin reduce Cure and Recurrence rates compared to Vancomycin in Clostridium Difficile Infection patients?: A Systematic Review and Meta-analysis

GAIMS Journal of Medical Sciences, 2022
Introduction We searched the databases to include randomized studies evaluating the effect of fidaxomicin on cure and recurrence rate in Clostridium difficile infection (CDI). Due to its increasing severity and recurrence rates, decrease in cure rates,
Hiral N Golakiya, Tejas M Khakhkhar, Neelesh Khuteta   +2 more
doaj   +1 more source

New Structure Activity Relationship Insight into the Role of the C-3 Extension on Rifamycin Antimycobacterial Activity. [PDF]

ChemMedChem
Rifamycin analogues with variably functionalized C‐3 extensions provide new insight into the role of this region for MTb inhibitory activity. In addition to potentially optimizing target engagement, this region can also be used to modulate physicochemical properties, an important consideration for optimizing antimycobacterial activity.
Veale CGL, Smolarz E, Leśniewska A, Pyta K, Przybylski P.   +4 more
europepmc   +2 more sources

A Novel Treatment Approach to Treatment-Resistant, Recurrent Clostridium difficile

Case Reports in Gastroenterology, 2022
A 36-year-old male with a previous medical history of persistent Clostridium difficile presented to clinic for evaluation of diarrheal symptoms intermittently for the last 2 years. He reported recurrent episodes of C. difficile that initially began after
Megha Gangadhar, Anita Kottapalli, Ven Kottapalli   +2 more
doaj   +1 more source

Fidaxomicin [PDF]

pharma-kritik, 2015
Eine intestinale Infektion mit Clostridium difficile kann zu einer Kolitis und weiteren Darm-Komplikationen führen. Fidaxomicin ist ein neues Antibiotikum, das zur Behandlung einer solchen Erkrankung eingesetzt werden kann, wenn andere Medikamente (Metronidazol, Vancomycin) nicht genügen.
openaire   +1 more source

Recent Advances in Mode of Action and Biosynthesis Studies of the Clinically Used Antibiotic Fidaxomicin

CHIMIA, 2020
The natural product antibiotic fidaxomicin is a marketed drug for the treatment of bacterial infections in the gut. Due to its promising in vitro activities against Mycobacterium tuberculosis, the development of next generation fidaxomicin analogs is of ...
Andrea Dorst, Erik Jung, Karl Gademann
doaj   +1 more source

Fidaxomicin for the Treatment of Clostridioides difficile Infection in Adult Patients: An Update on Results from Randomized Controlled Trials

Antibiotics, 2022
In recently updated international guidelines, fidaxomicin is preferentially recommended as first-line treatment over vancomycin both for the first episode of CDI and for rCDI, based on the results of different randomized controlled trials (RCTs ...
Daniele Roberto Giacobbe, Antonio Vena, Marco Falcone, Francesco Menichetti, Matteo Bassetti   +4 more
doaj   +1 more source

Antibiotic fidaxomicin is an RdRp inhibitor as a potential new therapeutic agent against Zika virus

BMC Medicine, 2020
Background Zika virus (ZIKV) infection is a global health problem, and its complications, including congenital Zika syndrome and Guillain-Barré syndrome, constitute a continued threat to humans.
Jie Yuan, Jianchen Yu, Yun Huang, Zhenjian He, Jia Luo, Yun Wu, Yingchun Zheng, Jueheng Wu, Xun Zhu, Haihe Wang, Mengfeng Li   +10 more
doaj   +1 more source

Retrospective evaluation of fidaxomicin versus oral vancomycin for treatment of Clostridium difficile infections in allogeneic stem cell transplant

Hematology/Oncology and Stem Cell Therapy, 2018
Objective/background: Clostridium difficile infection (CDI) is a potential complication during hematopoietic stem cell transplantation (HSCT), and no specific recommendations exist regarding treatment of CDI in allogeneic SCT patients.
Laura Prohaska, Zahra Mahmoudjafari, Leyla Shune, Anurag Singh, Tara Lin, Sunil Abhyankar, Siddhartha Ganguly, Dennis Grauer, Joseph McGuirk, Lisa Clough   +9 more
doaj   +1 more source

Retrospective Cohort Analysis of Outpatient Antibiotic Use for Clostridioides difficile-Indicated Agents in British Columbia, from 2000 to 2018

Canadian Journal of Infectious Diseases and Medical Microbiology, 2023
Background. Clostridioides difficile (CDI) is the most common cause of nosocomial diarrheal infections. Historically, metronidazole was the first-line treatment, but guidelines now indicate oral vancomycin and fidaxomicin as primary antibiotics for ...
Ariana Saatchi, Sungeun Kim, Fawziah Marra   +2 more
doaj   +1 more source